PLGA from PolySciTech used in development of delivery system for mallotumide A as a treatment for triple negative breast cancer

 

Mallotumide is a cycloheptapeptide with anticancer activity. To this date, triple-negative breast cancer remains resistant to most treatment options. Researchers at Mahidol University and Academia Sinica, PLGA (AP059, https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AP059#h) from PolySciTech : Akina, Inc. (www.PolySciTech.com) to develop a targeted, nanoparticle for anticancer therapy towards this form of breast cancer. This research holds promise to provide for treatment against breast cancer. Read more: Manohong, Preeyanuch, Natthapat Sawektreeratana, Sopon Nuchpun, Tipaporn Kumkoon, Pattaree Payomhom, Chayanee Laowittawat, Sarawut Jitrapakdee et al. "Encapsulation of Plant‐Derived Cycloheptapeptide Mallotumide A in Riboflavin‐Modified Poly (Lactic‐Co‐Glycolic Acid)/Chitosan Nanoparticles." Macromolecular Materials and Engineering 311, no. 1 (2026): e00385. https://onlinelibrary.wiley.com/doi/full/10.1002/mame.202500385

“Mallotumide A (MA) is a novel cycloheptapeptide isolated from the roots of Mallotus spodocarpus Airy Shaw. It exerts anticancer activity by downregulating several lipogenic enzymes and cellular respiration, particularly in triple-negative breast cancer. However, MA has poor water solubility and is highly toxic to both cancer and normal cells, limiting its therapeutic applications. To address these drawbacks, MA was encapsulated within poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) and coated with riboflavin (Rf)-modified chitosan (CR), creating (MA)PLGA/CR NPs. This study characterized the NPs and investigated their encapsulation efficiency of MA, cellular uptake, and anticancer activity in two breast cancer (MDA-MB-231 and MCF-7) and normal (MCF-10A) cell lines. The NPs were spherical with an average size of 300 ± 6.64 nm and a zeta potential of +11.96 mV. The PLGA/CR NPs exhibited enhanced cellular uptake in both cancer cells in a dose- and time-dependent manner, while reducing toxicity in normal cells. Furthermore, the (MA)PLGA/CR NPs inhibited the viability, migration, and invasion of MDA-MB-231 cells, thereby demonstrating their potential as a targeted anticancer delivery system.”

Benchtop to Bedside with MidWest GMP https://www.akinainc.com/midwestgmp/

Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

Ashland-TM Polymer Products: https://akinainc.com/polyscitech/products/ashland/